Can GLP-1 medications reduce visceral fat specifically?

GLP-1 receptor agonists (semaglutide, tirzepatide) preferentially reduce visceral fat more than subcutaneous fat during weight loss, the ratio of visceral to total fat loss in GLP-1 trial participants is consistently higher than with lifestyle-only weight loss of the same magnitude, driven by the medications' effects on hepatic fat metabolism, appetite suppression reducing particularly caloric-dense food intake, and possible direct effects on adipose tissue GLP-1 receptors (Wilding et al., NEJM, 2021).

DEXA and MRI imaging substudy data from GLP-1 trials show disproportionate visceral adipose tissue reduction, men losing 15% total body weight on semaglutide are losing proportionally more than 15% of their visceral fat. This is clinically relevant because visceral fat drives cardiovascular risk more directly than total fat. The SELECT trial's cardiovascular mortality benefit from semaglutide in men without diabetes (20% reduction in MACE) is likely partly mediated through this preferential visceral fat reduction and its downstream inflammatory effects.

Honesty Scale: Solid (1) for GLP-1 agents producing disproportionate visceral fat reduction. Solid (1) for semaglutide reducing MACE in the SELECT trial.

What to do: For men with significant visceral fat accumulation who have not achieved adequate reduction with lifestyle intervention alone, GLP-1 receptor agonists are a legitimate medical option to discuss with a cardiologist or internist. They are not a lifestyle substitute, they work best when combined with dietary changes and exercise.

For the full picture, read The Visceral Fat Deep Dive